Lilly and UnitedHealth Group partnered on pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19

,

On Dec. 4, 2020, Eli Lilly and UnitedHealth Group announced a partnership to conduct a pragmatic study of bamlanivimab (LY-CoV555) in high-risk, COVID-19 infected individuals. The trial evaluated the efficacy and safety of bamlanivimab versus a propensity-matched control in individuals that meet the EUA criteria.

Tags:

Source: Eli Lilly
Credit:

Visit News/History Source
Transfection Has Never Been So Easy With Avalanche® Transfection Reagents for Cancer Cells, Primary Cells, And Other Difficult-To-Transfect Cells.Primary Cells, And Other Difficult-To-Transfect Cells.